BYSI

BeyondSpring Inc

BYSI, USA

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

https://beyondspringpharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
BYSI
stock
BYSI

BYSI Stock Volatility Amidst Strategic Developments and Market Shifts StocksToTrade

Read more →
BYSI
stock
BYSI

BYSI Stock Shows Turbulence Amid Financial Uncertainty StocksToTrade

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$1.25

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-2.81

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

4.85 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-5.22 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 16.85% of the total shares of BeyondSpring Inc

1.

Decheng Capital LLC

(11.2354%)

since

2025/06/30

2.

BlackRock Inc

(1.5746%)

since

2025/06/30

3.

Vanguard Group Inc

(1.2985%)

since

2025/06/30

4.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8539%)

since

2025/07/31

5.

Geode Capital Management, LLC

(0.6353%)

since

2025/06/30

6.

Fidelity Extended Market Index

(0.2205%)

since

2025/07/31

7.

Fidelity Total Market Index

(0.1968%)

since

2025/07/31

8.

iShares Micro-Cap ETF

(0.1623%)

since

2025/08/31

9.

Fidelity Series Total Market Index

(0.1057%)

since

2025/07/31

10.

Extended Equity Market Fund K

(0.1022%)

since

2025/06/30

11.

Tanaka Capital Management Inc

(0.0652%)

since

2025/03/31

12.

Spartan Total Market Index Pool G

(0.0594%)

since

2025/07/31

13.

Fidelity Nasdaq Composite Index

(0.0585%)

since

2025/07/31

14.

Vanguard U.S. Eq Idx £ Acc

(0.0555%)

since

2025/07/31

15.

Northern Trust Corp

(0.0404%)

since

2025/06/30

16.

Renaissance Technologies Corp

(0.0288%)

since

2025/06/30

17.

Morgan Stanley - Brokerage Accounts

(0.0204%)

since

2025/06/30

18.

Bank of America Corp

(0.0193%)

since

2025/06/30

19.

UBS Group AG

(0.0172%)

since

2025/06/30

20.

1290 VT Micro Cap K

(0.015%)

since

2025/07/31

21.

AVIP BlackRock Advtg Small Cp Gr Prtfl

(0.0134%)

since

2025/06/30

22.

Northern Small Cap Core I

(0.0132%)

since

2025/06/30

23.

Extended Equity Market Fund M

(0.0129%)

since

2025/06/30

24.

Spartan Extended Market Index Pool F

(0.012%)

since

2025/07/31

25.

BlackRock Advtg Asia ex Jpn Eq D GBP Acc

(0.0083%)

since

2025/05/31

26.

NT Quality SCC US Fund - L

(0.0077%)

since

2025/06/30

27.

NT Quality Small Cap Core

(0.0077%)

since

2025/06/30

28.

Trifecta Capital Advisors LLC

(0.0037%)

since

2025/06/30

29.

Steward Partners Investment Advisory, LLC

(0.0027%)

since

2025/06/30

30.

Fidelity U.S. Equity Index Ins Trust

(0.0012%)

since

2025/07/31

31.

Tower Research Capital LLC

(0.0006%)

since

2025/06/30

32.

JPMorgan Chase & Co

(0.0004%)

since

2025/06/30

33.

Guggenheim Active Allocation Fund

(0.0003%)

since

2025/05/31

34.

SBI Securities Co Ltd

(0.0002%)

since

2025/06/30

35.

BNP Paribas Arbitrage, SA

(0%)

since

2025/06/30

36.

Barclays PLC

(0%)

since

2025/03/31

37.

Wells Fargo & Co

(0%)

since

2025/03/31

38.

Banque Transatlantique

(0%)

since

2025/06/30

39.

Citadel Advisors Llc

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(1)
Value
Overpriced(1)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.